2016ASCO免疫治疗进展分析.pptx

免疫治疗进展2016ASCO 3280A目前的在研项目-联合化疗 A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer [IMpower 132] 3280A目前的在研项目-辅助化疗后维持 Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] 9029 durvalumab (MEDI4736)治疗初治晚期NSCLC的临床疗效和安全性 Durvalumab (MEDI4736)是一种经过修改的人类IgG1抗体，阻断PD-L1与PD-1和CD80的结合，继而发挥抗肿瘤作用。 方法：对于经病理或细胞学证实的鳞癌